Key Takeaways

• Start with a clear target, intended application, and measurable criteria for a useful VHH.
• Antigen suitability, assay design, and species coverage influence the discovery plan and deliverables.
• Sequence files, purified candidates, characterization, and development support should be listed explicitly in the scope.
• Pricing, sample requirements, minimum order quantities, and lead times depend on the selected workflow and are best confirmed in a project-specific quotation.

Who This Guide Is For

This guide is intended for veterinary diagnostics developers, animal-health companies, research teams, and procurement specialists considering custom VHH development. It is useful whether you need a research reagent, a binder for an assay, or an early-stage candidate for further evaluation. It is not a substitute for product-specific validation or regulatory advice. Buyers should distinguish discovery-stage evidence from performance demonstrated in a finished diagnostic or therapeutic product.

What a Custom VHH Discovery Project Covers

Understanding VHHs and Discovery Options

VHHs are single-domain antibody fragments associated with camelid antibodies. A typical VHH is approximately 12–15 kDa and around 110–130 amino acids long, although individual sequences vary. These figures describe a general molecular format, not a guaranteed specification for every candidate. A discovery project may use an immune, naïve, or synthetic source, depending on the provider’s available platform, target, and agreed project design.

For an immune-library approach, an animal is exposed to an antigen under an appropriate immunization and oversight plan before antibody sequences are identified. Naïve or synthetic libraries can be alternatives when immunization is unsuitable or a defined sequence source is preferred. Each approach has trade-offs, and no library type guarantees a binder or a particular level of affinity. Ask the provider to explain which method is available and why it fits your target.

Matching the Project to a Veterinary Application

Application requirements should guide candidate selection from the start. A VHH intended for a livestock pathogen assay may need to recognize a conserved epitope, while a companion-animal test may require discrimination between closely related organisms or strains. If the product is intended to detect a soluble biomarker, the assay may need to work in a specific matrix such as serum, plasma, milk, or a swab extract. State whether you need binding to purified antigen, native protein, whole cells, or another target presentation.

Specify the species and sample context rather than saying only “veterinary use.” For example, a project may need reactivity to a target from one animal species, broad reactivity across several species, or limited cross-reactivity with related proteins. These are different screening objectives and may require different controls. A discovery-stage binder should not be assumed to work in a field test without assay development and validation.

Typical Workflow and Deliverables

1. Define the Target and Success Criteria

Share the target name, sequence or accession where available, species of origin, known variants, and the biological form you want recognized. Include the intended assay and the minimum evidence needed to advance a candidate. Useful criteria may include target binding, specificity against related proteins, performance in a stated matrix, or compatibility with a capture-and-detection pair.

2. Review Antigen and Project Readiness

The supplier will need information about antigen format, purity, concentration, buffer, storage history, and available quantity. Where relevant, provide expression system, tag, oligomeric state, and whether the antigen is expected to retain native conformation. If the antigen is not ready, ask whether the provider can advise on preparation or whether antigen production should be quoted separately. Confirm biosafety classification and shipment conditions before sending any biological material.

3. Select a Discovery and Screening Strategy

The agreed workflow may include library selection, enrichment, clone screening, sequencing, and candidate ranking. Some projects use multiple rounds of selection; two to four rounds can serve as an illustrative planning range, but the actual number is protocol-dependent and should not be treated as a universal requirement. Screening design matters as much as round count: include counter-selection or related-target controls when specificity is important. Ask how positive and negative results will be defined.

4. Confirm and Characterize Candidates

Shortlisted sequences may be expressed and tested in a format agreed with the buyer. Depending on scope, characterization can include binding confirmation, relative ranking, specificity checks, or an application-relevant assay. Binding results obtained with purified antigen do not by themselves establish sensitivity, selectivity, or robustness in a veterinary sample matrix. Request the method, controls, and interpretation criteria alongside any reported results.

For more information, please visit NBbiolab.

5. Transfer the Agreed Deliverables

Potential deliverables include VHH amino acid and nucleotide sequences, candidate identifiers, screening or characterization summaries, and purified protein when included in the quotation. DNA constructs, expression materials, additional characterization, and assay-development support may be separate line items. Confirm ownership, permitted use, confidentiality, and any limitations on redistribution before the project begins. The final statement of work should make clear what is included and what is not.

Project Requirements and Buyer Selection Framework

A complete project brief reduces avoidable redesign and makes supplier proposals easier to compare. Provide the following information as early as possible:

• Target: identity, species, sequence, variants, and relevant related targets.
• Antigen: format, quantity, concentration in mg/mL, buffer, purity information, and shipping requirements.
• Application: intended assay, sample matrix, species tested, and whether the goal is research use or product development.
• Performance priorities: binding, specificity, cross-reactivity, stability, or compatibility with a partner binder.
• Project logistics: desired deliverables, decision milestones, budget range, and any schedule constraints.

Use a written selection framework when comparing providers. Check whether the proposed discovery route fits your target, whether screening controls reflect your use case, and whether the quote separates discovery from expression and characterization. Clarify how many candidates or sequences are included, what data accompany them, and whether repeat work is included if initial screening does not meet agreed criteria. Avoid comparing headline prices without comparing scope.

Pricing, Minimum Order Quantities, and Lead Time

Custom discovery is generally scoped as a project rather than selected from a standard catalog, so total cost depends on the target, library strategy, antigen readiness, screening depth, and requested follow-up work. If purified VHH is required, confirm the amount, format, purity expectations, and whether expression is priced per candidate or as a separate service. Minimum order quantities, where applicable, can differ between discovery work and later protein production. NBbiolab can provide a project-specific quotation after reviewing the technical brief.

Lead time also depends on project design, sample availability, selection and screening needs, and the number of candidates requiring confirmation. Ask the supplier to identify the expected start point, major milestones, and factors that could change the schedule. Treat any preliminary estimate as conditional until the scope and material readiness are confirmed. For time-sensitive veterinary programs, build in time for assay testing in the intended sample matrix after candidate delivery.

Common Project Risks and How to Reduce Them

Unclear Target Presentation

A recombinant fragment may not represent the native form needed for an assay, particularly when folding, processing, or complex formation affects the recognized epitope. Share the biological context and ask whether the supplied antigen is appropriate for the intended application. Where feasible, plan confirmation against a second target format or relevant sample material.

Success Defined Only as “Binding”

Binding to a purified target is only one milestone. A useful veterinary reagent may also need to distinguish related species, tolerate matrix interference, or function in a particular assay format. Agree on the evidence required to advance a candidate before screening begins, and keep discovery success separate from finished-product performance claims.

Incomplete Scope and Transfer Terms

Projects can become difficult to evaluate when sequence ownership, protein quantities, data packages, or additional testing are left implicit. Put these items in the quotation or statement of work, including what happens if a requested deliverable is unavailable. Also confirm material handling, confidentiality, and any regulatory or ethical responsibilities that remain with the buyer.

Supplier Evaluation Checklist

• Can the supplier explain its proposed discovery strategy and its limitations for your target?
• Are antigen acceptance requirements and sample-handling instructions documented?
• Are screening controls and candidate advancement criteria aligned with your veterinary use case?
• Does the quote itemize sequences, protein production, characterization, and optional support?
• Are timeline assumptions, minimum quantities, ownership, and data transfer terms clear?

Conclusion: Prepare a Decision-Ready VHH Brief

A custom VHH discovery service is most suitable when you have a defined target and need candidates selected around a specific veterinary application. The core workflow is target and antigen review, discovery strategy selection, screening, candidate confirmation, and delivery of the items agreed in the project scope. The most important preparation is to specify species, sample matrix, target presentation, cross-reactivity needs, and what evidence will count as success. These inputs help determine whether the proposed service fits your technical and commercial requirements.

To start a discussion with NBbiolab, prepare your target information, antigen details, intended application, preferred deliverables, and approximate schedule. We can review the brief and clarify which discovery and follow-up options should be included in a project-specific proposal. This makes the next step a scope review rather than an assumption that every VHH project follows the same workflow or price.